|
1
|
Laver NV, McLaughlin ME and Duker JS:
Ocular melanoma. Arch Pathol Lab Med. 134:1778–1784.
2010.PubMed/NCBI
|
|
2
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment, and survival.
Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh P and Singh A: Choroidal melanoma.
Oman J Ophthalmol. 5:3–9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finger PT: Radiation therapy for choroidal
melanoma. Surv Ophthalmol. 42:215–232. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finger PT: Transpupillary thermotherapy in
choroidal melanoma. Ophthalmology. 104:731–732. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oosterhuis JA, Journée-de Korver HG and
Keunen JE: Transpupillary thermotherapy: Results in 50 patients
with choroidal melanoma. Arch Ophthalmol. 116:157–162. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilson MW and Hungerford JL: Comparison of
episcleral plaque and proton beam radiation therapy for the
treatment of choroidal melanoma. Ophthalmology. 106:1579–1587.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gragoudas ES, Egan KM, Seddon JM, Glynn
RJ, Walsh SM, Finn SM, Munzenrider JE and Spar MD: Survival of
patients with metastases from uveal melanoma. Ophthalmology.
98:383–390. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rogosnitzky M and Danks R: Therapeutic
potential of the biscoclaurine alkaloid, cepharanthine, for a range
of clinical conditions. Pharmacol Rep. 63:337–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gulcin I, Elias R, Gepdiremen A, Chea A
and Topal F: Antioxidant activity of bisbenzylisoquinoline
alkaloids from Stephania rotunda: Cepharanthine and fangchinoline.
J Enzyme Inhib Med Chem. 25:44–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furusawa S, Wu J, Fujimura T, Nakano S,
Nemoto S, Takayanagi M, Sasaki K and Takayanagi Y: Cepharanthine
inhibits proliferation of cancer cells by inducing apoptosis.
Methods Find Exp Clin Pharmacol. 20:87–97. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kikukawa Y, Okuno Y, Tatetsu H, Nakamura
M, Harada N, Ueno S, Kamizaki Y, Mitsuya H and Hata H: Induction of
cell cycle arrest and apoptosis in myeloma cells by cepharanthine,
a biscoclaurine alkaloid. Int J Oncol. 33:807–814. 2008.PubMed/NCBI
|
|
13
|
Uthaisar K, Seubwai W, Srikoon P,
Vaeteewoottacharn K, Sawanyawisuth K, Okada S and Wongkham S:
Cepharanthine suppresses metastatic potential of human
cholangiocarcinoma cell lines. Asian Pac J Cancer Prev. 13:(Suppl).
S149–S154. 2012.
|
|
14
|
Biswas KK, Tancharoen S, Sarker KP,
Kawahara K, Hashiguchi T and Maruyama I: Cepharanthine triggers
apoptosis in a human hepatocellular carcinoma cell line (HuH-7)
through the activation of JNK1/2 and the downregulation of Akt.
FEBS Lett. 580:703–710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara
M, Kato M, Akhand AA, Hayakawa A, Takeuchi K, Hossain K, et al:
Cepharanthine activates caspases and induces apoptosis in Jurkat
and K562 human leukemia cell lines. J Cell Biochem. 82:200–214.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Z, Huang C, Yang YL, Ding Y, Ou-Yang
HQ, Zhang YY and Xu M: Inhibition of the STAT3 signaling pathway is
involved in the antitumor activity of cepharanthine in SaOS2 cells.
Acta Pharmacol Sin. 33:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seubwai W, Vaeteewoottacharn K, Hiyoshi M,
Suzu S, Puapairoj A, Wongkham C, Okada S and Wongkham S:
Cepharanthine exerts antitumor activity on cholangiocarcinoma by
inhibiting NF-kappaB. Cancer Sci. 101:1590–1595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morioka S, Ono M, Tanaka N and Orita K:
Synergistic activation of rat alveolar macrophages by cepharanthine
and OK-432. Gan To Kagaku Ryoho. 12:1470–1475. 1985.(In Japanese).
PubMed/NCBI
|
|
19
|
Furusawa S and Wu J: The effects of
biscoclaurine alkaloid cepharanthine on mammalian cells:
Implications for cancer, shock, and inflammatory diseases. Life
Sci. 80:1073–1079. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ita M, Halicka HD, Tanaka T, Kurose A,
Ardelt B, Shogen K and Darzynkiewicz Z: Remarkable enhancement of
cytotoxicity of onconase and cepharanthine when used in combination
on various tumor cell lines. Cancer Biol Ther. 7:1104–1108. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kato T and Suzumura Y: Potentiation of
antitumor activity of vincristine by the biscoclaurine alkaloid
cepharanthine. J Natl Cancer Inst. 79:527–532. 1987.PubMed/NCBI
|
|
22
|
Harada K, Ferdous T, Itashiki Y, Takii M,
Mano T, Mori Y and Ueyama Y: Effects of cepharanthine alone and in
combination with fluoropyrimidine anticancer agent, S-1, on tumor
growth of human oral squamous cell carcinoma xenografts in nude
mice. Anticancer Res. 29:1263–1270. 2009.PubMed/NCBI
|
|
23
|
Kisara S, Furusawa S, Murata R, Ogata M,
Hikichi N, Takayanagi Y and Sasaki K: Combined effects of
buthionine sulfoximine and cepharanthine on cytotoxic activity of
doxorubicin to multidrug-resistant cells. Oncol Res. 7:191–200.
1995.PubMed/NCBI
|
|
24
|
Zhou Y, Hopper-Borge E, Shen T, Huang XC,
Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, et
al: Cepharanthine is a potent reversal agent for MRP7
(ABCC10)-mediated multidrug resistance. Biochem Pharmacol.
77:993–1001. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shiraishi N, Akiyama S, Nakagawa M,
Kobayashi M and Kuwano M: Effect of bisbenzylisoquinoline
(biscoclaurine) alkaloids on multidrug resistance in KB human
cancer cells. Cancer Res. 47:2413–2416. 1987.PubMed/NCBI
|
|
26
|
Hotta T, Tanimura H, Yamaue H, Iwahashi M,
Tani M, Tsunoda T, Noguchi K, Mizobata S and Terasawa H:
Synergistic effects of tamoxifen and cepharanthine for
circumventing the multidrug resistance. Cancer Lett. 107:117–123.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Single B, Leist M and Nicotera P:
Simultaneous release of adenylate kinase and cytochrome c in cell
death. Cell Death Differ. 5:1001–1003. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salakou S, Kardamakis D, Tsamandas AC,
Zolota V, Apostolakis E, Tzelepi V, Papathanasopoulos P, Bonikos
DS, Papapetropoulos T, Petsas T and Dougenis D: Increased Bax/Bcl-2
ratio up-regulates caspase-3 and increases apoptosis in the thymus
of patients with myasthenia gravis. In Vivo. 21:123–132.
2007.PubMed/NCBI
|
|
29
|
Yang B, Johnson TS, Thomas GL, Watson PF,
Wagner B, Furness PN and El Nahas AM: A shift in the Bax/Bcl-2
balance may activate caspase-3 and modulate apoptosis in
experimental glomerulonephritis. Kidney Int. 62:1301–1313. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dhanasekaran DN and Reddy EP: JNK
signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bennett BL, Sasaki DT, Murray BW, O'Leary
EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et
al: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal
kinase. Proc Natl Acad Sci USA. 98:13681–13686. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen HM and Liu ZG: JNK signaling pathway
is a key modulator in cell death mediated by reactive oxygen and
nitrogen species. Free Radic Biol Med. 40:928–939. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nakano H, Nakajima A, Sakon-Komazawa S,
Piao JH, Xue X and Okumura K: Reactive oxygen species mediate
crosstalk between NF-kappaB and JNK. Cell Death Differ. 13:730–737.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Son Y, Cheong YK, Kim NH, Chung HT, Kang
DG and Pae HO: Mitogen-activated protein kinases and reactive
oxygen species: How Can ROS activate MAPK pathways? J Signal
Transduct. 2011:7926392011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ono M, Tanaka N and Orita K: Positive
interactions between human interferon and cepharanthin against
human cancer cells in vitro and in vivo. Cancer Chemother
Pharmacol. 35:10–16. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ito H, Ito H, Amano H and Noda H:
Inhibitory effect of a biscoclaurine alkaloid, cepharanthin, on
lung metastasis of Lewis lung carcinoma. Jpn J Pharmacol.
56:195–202. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rietschel P, Panageas KS, Hanlon C, Patel
A, Abramson DH and Chapman PB: Variates of survival in metastatic
uveal melanoma. J Clin Oncol. 23:8076–8080. 2005. View Article : Google Scholar : PubMed/NCBI
|
